Promising Antitumor Activity of a Novel Quinoline Derivative, TAS-103, against Fresh Clinical Specimens of Eight Types of Tumors Measured by Flow Cytometric DNA Analysis(Highlighted paper selected by Editor-in-chief,Biopharmacy)
スポンサーリンク
概要
- 論文の詳細を見る
TAS-103, 6-[[2-(dimethylamino)ethyl] amino] -3-hydroxy-7H-indeno-[2, 1-c] quinolin-7-one dihydrochloride, is a dual topoisomerases I and II inhibitor. Antitumor activities of TAS-103 against fresh surgical specimens resected from 525 patients (32 types of tumors) were examined by flow cytometric (FCM) analysis of DNA integrity of tumor cells, and compared with those of five other investigational new drugs and 31 clinically available anticancer agents. Concentrations of clinically available anticancer agents were set at one-tenth of the peak plasma concentration (PPC) of the clinically recommended doses. On the other hand, since PPCs of investigational new drugs in humans were frequently unknown, these were estimated by a method that determines the theoretically achievable concentration in body fluid (TAC method). Correlations between TAC and PPC were examined for 16 clinically available anticancer agents, and it was found that TAC at 7n (the modified Fibonacci's dose-escalation scheme) of 14 drugs corresponded well with each one-tenth of PPC. By defining a 30% or more reduction in the integrated diploid peak as effective and a 60% or more reduction as definitely effective, TAS-103 at 5μg/ml (7n) showed significantly higher effective rates and definitely effective rates than those of all other investigational new drugs, as well as almost all clinically available anticancer agents, against various malignancies, including non-small cell lung cancer, brain tumor and renal cancer. These results strongly suggest that TAS-103 will be expected to show excellent antitumor activities against a wide range of human tumors.
- 公益社団法人日本薬学会の論文
- 2007-10-01
著者
関連論文
- A COMPARISON OF A NEW NITROSOUREA DERIVATIVE, 1-(2-CHLOROETHYL)-3-ISOBUTYL-3-(β-MALTOSYL)-1-NITROSOUREA WITH VARIOUS ANTITUMOR AGENTS WITH RESPECT TO THERAPEUTIC RATIOS IN L1210 LEUKEMIA SYSTEMS
- Schedule-Dependent Antitumor Activity and Toxicity of Combinations of 5-Fluorouracil and Cisplatin/Carboplatin against L1210 Leukemia-Bearing Mice(Biopharmacy)
- Promising Antitumor Activity of a Novel Quinoline Derivative, TAS-103, against Fresh Clinical Specimens of Eight Types of Tumors Measured by Flow Cytometric DNA Analysis(Highlighted paper selected by Editor-in-chief,Biopharmacy)
- Schedule-dependent and -independent Antitumor Activity of Paclitaxel-based Combination Chemotherapy against M-109 Murine Lung Carcinoma in vivo
- ENHANCED ANTITUMOR ACTIVITY OF 5'-DEOXY-5-FLUOROURIDINE AGAINST LEWIS LUNG CARCINOMA IN AGED HYBRID (C57BL/6×DBA/2) F_1 MICE